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Background: Accurate risk stratification is considered the first and most important step in the management of
patients with non-valvular atrial fibrillation (NVAF). We compared the performance of the widely used CHA2DS2-VASc
and the recently developed R2CHADS2 and ATRIA scores, for predicting thromboembolic (TE) event in either
non-anticoagulated or anticoagulated patients with NVAF.
Methods: The non-anticoagulated cohort was comprised of 154 patients, whereas 911 patients formed the cohort of
patients on vitamin-K-antagonist. The scores were computed using the criteria mentioned in their developmental
cohorts. Measures of performance for the risk scores were evaluated at predicting TE event.
Results: In the non-anticoagulated cohort, 9 TE events occurred during 11 ± 2.7 months. CHA2DS2-VASc showed
significant association with TE occurrence: hazard ratio (HR) = 1.58 (95 % confidence interval [95 % IC] 1.01–2.46),
but R2CHADS2 and ATRIA did not (HR = 1.23 (95 % CI 0.86–1.77) and 1.20 (95 % CI 0.93–1.56), respectively.
In the anticoagulated cohort, after 10 ± 3 months of follow up, 18 TE events were developed. In that cohort, the
three scores showed similar association with TE risk: HR = 1.49 (95 % CI 1.13–1.97), 1.41 (95 % CI 1.13–1.77) and 1.37
(95 % CI 1.12–1.66) for CHA2DS2-VASc, R2CHADS2 and ATRIA, respectively.
In both cohorts, no TE event occurred in patients classified in the low risk category according to CHA2DS2-VASc or
R2CHADS2.
Conclusions: In this study of NVAF patients, CHA2DS2-VASc has better association with TE events than the new
R2CHADS2 and ATRIA risk scores in the non-anticoagulated cohort. CHA2DS2-VASc and R2CHADS2 can identify patients
at truly low risk regardless of the anticoagulation status.
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Atrial fibrillation (AF) increases the risk of embolic
stroke by 5-fold [1]. Effective prevention of thrombo-
embolic events (TE) with oral anticoagulants is the
cornerstone of AF management and appropriate TE risk
stratification is a critical step in the decision making
process regarding this vital issue [2].
The current clinical practice guidelines [3–5] recom-
mend the use of CHADS2 [6] and CHA2DS2-VASc [7]
risk scores in the effective TE prevention strategy.
CHADS2 [6] score was validated and conceived in the
year of 2001 with the aim of identifying patients at high
risk of TE events. However, patients at low risk accord-
ing to CHADS2 score continued to have significant an-
nual stroke rate [8, 9], this enhanced the motivation to
investigate the significance of other risk factors not in-
cluded in the CHADS2 score and, in turn, has led to a
clinical shift in the paradigm with a new aim to identify
“truly low risk” patients using CHA2DS2-VASc score [7].
Anyhow, in several studies, CHADS2 and CHA2DS2-
VASc showed just a moderate discrimination ability to
predict TE complications [10, 11], and at least one re-
cently published large cohort study demonstrated an
annual ischemic stroke rate of 1.06 % in the group of pa-
tients classified in “the true low risk category” according
to CHA2DS2-VASc [12]. All this could lead to a number
of questions and potential avenues for further research.
Recently, and with the aim to improve the ability to
predict TE event, two new TE risk scores (i.e. R2CHADS2
[13] and ATRIA [14]) have been shown, in their own der-
ivation cohorts, better performance than CHADS2 and
CHA2DS2-VASc. Really, the two recently proposed risk
scores contain new risk factors in their schemes which
were not included in the most recommended CHA2DS2-
VASc score. This fact could qualify them to strongly
capture the risk of suffering a future TE event, but little
information is available in this regard in independent data-
set of patients. A recent expert review has announced the
need for further validation of the R2CHADS2 in a real
world cohort with full spectrum of estimated glomerular
filtration rate (eGFR) [15].
We aimed to evaluate the ability of CHA2DS2-VASc,
R2CHADS2 and ATRIA scores at predicting TE events
in contemporary two different real world cohorts of
non-anticoagulated and anticoagulated patients with
non-valvular atrial fibrillation (NVAF) which have full
spectrum of eGFR.
Methods
This retrospective study is composed of two separate
and different cohorts: for the first cohort, we screened
all the consultations which were registered in the emer-
gency department of our tertiary hospital between January
2008 and June 2010, by this we were able to identify allconsecutive patients ≥18 years of age with AF docu-
mented by electrocardiographic records (n = 1873).
After excluding patients with prosthetic valve (n = 473),
rheumatic heart disease (n = 46) and/or patients with ac-
tive cancer (n = 61), there were 1293 patients with NVAF.
We also excluded patients on anticoagulation (n = 1135)
and those patients lost to follow up (n = 4). Thus, the non-
anticoagulated cohort consisted of 154 consecutive pa-
tients with NVAF.
The second cohort of the present study was consti-
tuted by 911 patients with NVAF on vitamin K antago-
nists (VKAs), as was previously described [16].
For both cohorts, a detailed medical history was recor-
ded for each patient, and the basal clinical characteristics
at study entry together with information on follow up
were carefully gathered by cardiologists.
The study was approved by the Clinical Research Ethics
Committee of the University Clinical Hospital of Santiago
de Compostela. The study protocol conforms to the eth-
ical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the institution’s human
research committee.
TE risk calculation
CHA2DS2-VASc, R2CHADS2 and ATRIA scores for pre-
dicting TE complications were calculated in each patient
from the original corresponding prognostic variables
scores used in their derivation cohorts. CHA2DS2-VASc
was calculated by adding 2 points for age ≥ 75 years; 2
points for prior stroke or transient ischemic attack (TIA);
and 1 point for each of the following factors: congestive
heart failure\left ventricular ejection fraction ≤40 %,
hypertension, diabetes mellitus, vascular disease, age 65–
74 and female sex, with a maximum score of 9 points.
R2CHADS2 was calculated by adding 2 points for renal
dysfunction (i.e. estimated glomerular filtration rate
[eGFR] <60 ml/min/1.73 m2); 2 points for prior stroke
or TIA; and one point for each of the following factors:
congestive heart failure, hypertension, age ≥ 75 and dia-
betes mellitus with a maximum score of 8 points.
For CHA2DS-VA2Sc and R2CHADS2, patients with 0
point were defined as being in the low risk category and
patients with 1 point were at intermediated risk, while
patients with ≥2 points were in the high risk stratum.
The ATRIA TE risk score was calculated by adding 1
point for each of the following factors: female sex, dia-
betes mellitus, congestive heart failure, hypertension,
proteinuria and renal dysfunction (i.e. eGFR < 45 ml/min/
1.73 m2 or end-stage renal disease) and by adding 0–9
points depending on the specific score weighting of pa-
tients age according to the presence or absence of prior
ischemic stroke [14]. We did not have data about protein-
uria, so the maximum score of the ATRIA risk score will
be 14 points. Patients with ≤ 5 points were defined as low
Table 1 Baseline characteristics of patients with nonvalvular






N = 154 N = 911
Age (years) 74 ± 12 73 ± 11
Age ≥65 years, % 127 (82.5) 707 (77.6)
Age ≥75 years, % 75 (40.5) 445 (48.8)
Female sex, % 81 (52.6) 306 (33.6)
Systolic blood pressure
at study entry (mmHg)
129 ± 15 139 ± 28
Current smoking, % 53 (30.4) 77 (8.5)
Hypertension, % 110 (71.4) 678 (74.4)
Diabetes mellitus, % 33 (21.4) 220 (24.1)
Peripheral arterial disease, % 20 (12.9) 92 (10.1)
Heart failure, % 10 (6.5) 343 (35.5)
History of stroke or TIA, % 9 (5.8) 103 (11.3)
Coronary artery disease, % 23 (14.9) 127 (13.9)
COPD, % 31 (20.1) 183 (20.1)
Hyperthyroidism, % 2 (1.3) 14 (1.5)
Anemia, % 27 (17.4) 178 (19.5)
Alcohol consumption
≥ 40 gr/daily, %
9 (5.8) 81 (8.9)
Antiplatelets, % 150 (97.4) 23 (2.5)
PINRR (%) -- 58 ± 18
eGFR < 60 ml/min/
1.73 m2, %
44 (28.6) 311 (34.1)
CHA2DS2-VASc
0 point, % 5 (3.2) 62 (6.8)
1 point, % 18 (11.7) 77 (8.4)
≥ 2 points, % 131 (85.1) 772 (84.7)
R2CHADS2
0 points, % 22 (14.3) 98 (10.8)
1 points, % 43 (27.9) 142 (15.6)
≥ 2 points, % 89 (57.8) 671 (73.7)
ATRIA
≤ 5 points, % 79 (51.3) 389 (42.7)
6 points, % 14 (9.1) 115 (12.6)
≥ 7 points, % 61 (39.6) 407 (44.7)
ATRIA the anticoagulation and risk factors in atrial fibrillation score, CHA2DS2-
VASc congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior
stroke or transient ischemic attack, vascular disease, age 65–74, female, COPD
chronic obstructive pulmonary disease, eGFR estimated glomerular filtration rate,
PINNR proportion of international normalized ratio within therapeutic range,
R2CHADS2 renal dysfunction, congestive heart failure, hypertension, age ≥75,
diabetes mellitus, prior stroke or transient ischemic attack, TIA transient
ischemic attack
Abumuaileq et al. BMC Cardiovascular Disorders  (2015) 15:156 Page 3 of 7risk category and patients with 6 points were at interme-
diated risk, while patients with ≥7 points were in the high
risk stratum.
eGFR was estimated at study entry for every patient in
both cohorts using the 4 variable Modification of Diet in
Renal Disease (MDRD-4) [17].
End point definition
The primary endpoint for the present study was the
development of TE event during follow-up. A TE com-
plication was defined as the occurrence of ischemic
stroke, TIA or peripheral embolism (including fatal TE
events). Diagnosis of stroke or transient ischemic attack
required an acute neurological deficit lasting for more or
less than 24 h, respectively, which could not be explained
by other causes and with at least 1 image test (computed
tomography or magnetic resonance) compatible with the
diagnosis, as well as confirmation from a neurologist. A
diagnosis of peripheral embolism was defined as non-
central nervous system embolism leading to an abrupt
vascular insufficiency associated with clinical or radio-
graphic evidence of arterial occlusion in absence of an-
other mechanism such as atherosclerosis, instrumentation
or trauma.
For both cohorts, patients were followed up for 1-year
after the enrolment or until TE event or death occurred.
Data on TE event were gathered from the cardiology
clinic visits and records, and through hospital files as
well as through primary care centers reports. Data regard-
ing death during the follow up period was also recorded.
Statistical analysis
Qualitative data were expressed as frequencies and per-
centages while quantitative data were summarized as
mean and standard deviation. Each risk score was en-
tered into separate Cox regression models to test their
association with TE complication. Thereafter, we calcu-
lated the c-statistic as a measure of the predictive ability
of the scores and tested the hypothesis that these schemes
performed significantly better than chance (indicated by a
c-statistic 0.50). We calculated and reported the p-values
and hazard ratios (HR) with their 95 % confidence interval
(95 % CI). P-value < 0.05 was considered statistically sig-




Our study enrolled a total of 1065 patients, distributed
in two different cohorts. The non-anticoagulated cohort
had 154 patients with NVAF and the anticoagulated co-
hort consisted of 911 patients with NVAF on VKAs.
Table 1 summarizes the baseline characteristics of the
patients in each cohort. For the non-anticoagulated cohortthe mean age was 74 ± 12 and 52.6 % were females. For
the anticoagulated cohort, the mean age was 73 ± 11 and
33.6 % were females.
Table 3 Association between each risk score as continuous
variables and thromboembolic event in both cohorts
Non anticoagulated cohort Anticoagulated cohort
HR (95 % CI) HR (95 % CI)
CHA2DS2-VASc 1.58 (1.01–2.46) 1.49 (1.13–1.97)
p = 0.044 p = 0.005
R2CHADS2 1.23 (0.86–1.77) 1.41 (1.13–1.77)
p = 0.25 p = 0.03
ATRIA 1.20 (0.93–1.56) 1.37 (1.12–1.66)
p = 0.17 p = 0.002
ATRIA the anticoagulation and risk factors in atrial fibrillation score, CHA2DS2-
VASc congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior
stroke or transient ischemic attack, vascular disease, age 65–74, female, CI
confidence interval, HR hazard ratio, NVAF nonvalvular atrial fibrillation, p;
p value, R2CHADS2 renal dysfunction, congestive heart failure, hypertension,
age ≥75, diabetes mellitus, prior stroke or transient ischemic attack
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During follow up (11 ± 2.7 months) of the non-
anticoagulated cohort, 8 (5.2 %) patients died and 9 (5.8 %)
patients developed TE events, 8 of them were ischemic
strokes and one event was a peripheral embolic event. For
the anticoagulated cohort, 60 (6.6 %) patients died and 18
(2 %) patients developed TE events during the follow up
(10 ± 3 months): 13 events were ischemic strokes, 2 events
were TIAs and 3 were peripheral embolic events.
Risk scores performance
Risk scores performance in the non-anticoagulated cohort
CHA2DS2-VASc score classified 85.1 % of patients in the
high risk category, while R2CHADS2 classified 57.8 % as
high risk patients; ATRIA classified just 39.6 % of patients
in the high risk category (Table 1).
The distribution of the TE events rates in the different
risk categories of the three risk scores, demonstrated the
absence of occurrence of TE event in the subgroups of
patients classified as low risk (i.e. patients with 0 point)
according to CHA2DS2-VASc and R2CHADS2. However,
TE events occurred in 6.3 % of patients classified as at
low risk according to ATRIA (Table 2).
CHA2DS2-VASc was the only score to show significant
association with TE events: HR = 1.58 (95 % CI; 1.01–
2.46). R2CHADS2 and ATRIA did not show significant as-
sociation with TE event: HR = 1.23 (95 % CI; 0.86–1.77)
and 1.20 (95 % CI; 0.93–1.56) for both scores, respectively
(Table 3).
The discriminative capacity of the three risk scores at
predicting TE event are shown in Table 4. CHA2DS2-Table 2 Distribution of thromboembolic events according to
the different risk category of each risk score
Non-anticoagulated cohort Anticoagulated cohort
N = 9 N = 18
CHA2DS2-VASc
0 point, % 0 (0) 0 (0)
1 point, % 0 (0) 1 (1.3)
≥ 2 points, % 9 (6.9) 17 (2.2)
R2CHADS2
0 point, % 0 (0) 0 (0)
1 point, % 1 (2.3) 0 (0)
≥ 2 points, % 8 (9) 18 (2.7)
ATRIA
≤ 5 points, % 5 (6.3) 2 (0.5)
6 points, % 0 (0) 1 (0.9)
≥ 7 points, % 4 (6.6) 15 (3.7)
ATRIA the anticoagulation and risk factors in atrial fibrillation score, CHA2DS2-
VASc congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior
stroke or transient ischemic attack, vascular disease, age 65–74, female,
R2CHADS2 renal dysfunction, congestive heart failure, hypertension, age ≥75,
diabetes mellitus, prior stroke or transient ischemic attackVASc and R2CHADS2 had moderate discriminative cap-
acity with c-statistics of 0.69 (95 % CI; 0.53–0.85) and
0.65 (95 % CI; 0.53–0.78), respectively. The ATRIA score
showed a weaker discriminative ability at predicting TE
events: c- statistics = 0.64 (95 % CI; 0.49–0.80).
Risk scores performance in the anticoagulated cohort
CHA2DS2-VASc score classified 84.7 % of patients in the
high risk category, while R2CHADS2 classified 73.7 % and
ATRIA classified just 44.7 % of patients in the high risk
category (Table 1).
The distribution of the TE events rates in the different
risk categories showed the absence of TE event in pa-
tients classified in the low risk category according to
CHA2DS2-VASc and R2CHADS2. However, two TE
events occurred among patients belonged to the low risk
category by ATRIA (Table 2).
In terms of hazard ratios, as a measure of association
between each risk score and TE events, all the studied
scores demonstrated similar and significant associ-
ation with TE events: HR = 1.49 (95 % CI; 1.13–1.97),
1.41 (95 % CI; 1.13–1.77) and 1.37 (95 % CI; 1.12–1.66)
for CHA2DS2-VASc, R2CHADS2 and ATRIA, respectively
(Table 3).Table 4 Discriminatory capacity of risk scores as continuous
variables at predicting thromboembolic event in both cohorts
Non anticoagulated cohort Anticoagulated cohort
c-statistics (95 % CI) c-statistics (95 % CI)
CHA2DS2-VASc 0.69 (0.53–0.85) 0.72 (0.63–0.82)
R2CHADS2 0.65 (0.53–0.78) 0.70 (0.61–0.79)
ATRIA 0.64 (0.49–0.80) 0.72 (0.62–0.83)
ATRIA the anticoagulation and risk factors in atrial fibrillation score, CHA2DS2-
VASc congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior
stroke or transient ischemic attack, vascular disease, age 65–74, female, CI
confidence interval, HR hazard ratio, R2CHADS2 renal dysfunction, congestive
heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient
ischemic attack
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at predicting TE event: c-statistics = 0.72 (95 % CI; 0.63–
0.82) for CHA2DS2-VASc; 0.70 (95 % CI; 0.61–0.79) for
R2CHADS2 and 0.72 (95 % CI; 0.62-0.83) for ATRIA
(Table 4).
Discussion
In this study comparing three contemporary TE risk scores
in non-anticoagulated and anticoagulated real world co-
horts of patients with NVAF which have full spectrum of
eGFR, CHA2DS2-VASc was the only score to show signi-
ficant association in terms of hazard ratio at predicting TE
events in the non-anticoagulated cohort.
In the anticoagulated cohort of this study, the three
TE risk scores had similar and significant association
and discrimination at predicting TE event. On note, only
the CHA2DS2-VASc and R2CHADS2 were accurate at
defining patients at truly low risk to develop TE event in
both cohorts.
Oral anticoagulants are highly effective in preventing
TE event in patients with AF. However, risk of major
bleeding is the downside of oral anticoagulants therapy,
so accurate risk estimation of TE event is of paramount
importance to help decision making process regarding
this issue [2]. Up to our knowledge, this is the first study
to compare the most recommended CHA2DS2-VASc
and the recently developed and more sophistically derived
R2CHADS2 and ATRIA scores in real world non-
anticoagulated and anticoagulated patients with NVAF.
It is clearly recognized that TE risk scores are best
tested in a non-anticoagulated cohort from a real world
[15]. In this regard, although R2CHADS2 and ATRIA
contained new risk factors believed to have strong asso-
ciation with TE event like renal dysfunction [13, 14, 18].
However, CHA2DS2-VASc was the best score to have
strong association with TE event in the non-anticoagulated
cohort of our study, this may be explained by the fact that
factors like renal dysfunction may coexist with advancing
age, hypertension, diabetes, heart failure and vascular dis-
ease which are already individual components comprising
the CHA2DS2-VASc score. Moreover, our results can be
explained and supported if we take into account that
R2CHADS2 score [13] was mainly derived and validated
from the ROCKET AF trial of anticoagulated patients
which excluded patients with creatinine clearance < 30 ml/
min and this may limit its predictability in non-
anticoagulated AF patients from the real world with full
range of eGFR. Furthermore, similar to our findings in
which CHA2DS2-VASc clearly outperformed ATRIA score
in non-anticoagulated cohort of patients with AF, were
found in a recent nationwide study [12].
The analysis of the anticoagulated cohort of the
current study showed that the three TE risk scores have
demonstrated similar association and discrimination atpredicting thromboembolism. The improvement we
have seen in the performance of the R2CHADS2 and
ATRIA in the anticoagulated cohort may be explained
by the fact that factors like renal dysfunction ─which is
involved in the R2CHADS2 and ATRIA─ is a strong inde-
pendent predictor of poor anticoagulation control and
hence for more TE complications [16, 19]. Furthermore,
these findings, in turn, may reflect that the non-
anticoagulated and the anticoagulated cohorts of patients
with NVAF are completely different groups of patients
and re-emphasized the belief and strong hypothesis that
TE risk scores are best tested in a non-anticoagulated
cohort.
In our analysis, CHA2DS2-VASc and R2CHADS2 were
accurate at identifying truly low risk patients in both
cohorts. In previous studies, CHA2DS2-VASc had identi-
fied accurately patients at low risk in non-anticoagulated
and anticoagulated patients with NVAF [7, 20]. Simi-
lar to our results regarding the reasonable ability of
R2CHADS2 at identifying patients at low risk, were found
in the external validation of R2CHADS2 in which the rates
of TE event in the low risk patients at 3-years of follow up
were as low as 0.36 % and 0.5 % in the non-anticoagulated
and anticoagulated subgroups of the ATRIA study cohort,
respectively [13].
In the two different cohorts of current study, ATRIA
classified about half of patients in the low risk category,
and this may limit its ability to correctly classify patients
at truly low risk. Similar performance of the ATRIA risk
score was found in a recent study enrolled large cohort
of patients [12].
Similar to our findings in which CHA2DS2-VASc clas-
sified the greatest number of patients as being at high
risk (85.1 %) and (84.7 %) in the non-anticoagulated and
anticoagulated cohorts, respectively, were reported pre-
viously [12, 20]. This may aid and reflect the accuracy of
CHA2DS2-VASc at classifying a small group of patients
who are truly at low risk of TE event.
Finally, our analysis of the anticoagulated cohort
showed that those patients in the high risk category ac-
cording to CHA2DS2-VASc and the R2CHADS2 are still
at high risk of developing TE event despite anticoagula-
tion. Really, the identification of patients who remain at
high risk of TE event despite anticoagulation could be of
great importance in daily clinical practice as this high
risk group of patients may need specific treatment strat-
egy with close follow up and more efforts to improve the
quality of anticoagulation control and to achieve the best
management of their risk factors like hypertension, dia-
betes and heart failure.
Although this is the first study aimed to compare the
CHA2DS2-VASc and the new R2CHADS2 and ATRIA
scores in real world non-anticoagulated and anticoa-
gulated cohorts of patients with NVAF. However, the
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study - when compared with several previous studies
[12–14] - might limit the validity of our results. This
might reflect the need for future studies with large
cohorts of patients for further validation of the inter-
esting results obtained from our analysis.
Our overall results when taken together might indicate
that the CHA2DS2-VASc still the best user friendly tool
at predicting TE event as well as at identifying patients at
truly low risk particularly in the non-anticoagulated pa-
tients who are actually need accurate TE risk stratification.
Limitations
The main limitation of our study is its retrospective
design, but it has interesting strong points as it reflects
real world practice by enrolment of two contemporary
separate and different cohorts of non-anticoagulated and
anticoagulated patients with NVAF consulted the emer-
gency department or the outpatient cardiology clinics of
a tertiary hospital with the advantage of careful follow-
up and data collection by cardiologists. Nevertheless, in
this regard prospective studies in the future may be
needed for better assessment of the clinical validity of
our results.
The sample size of the non-anticoagulated cohort of
the current study might be another limitation of our
study that could limit the likelihood of detecting small
effects or significant relationships from the data. However,
the availability of a contemporary large non-anticoagulated
cohort of patients with NVAF is challenging and in-
creasingly unlikely. Furthermore, the findings in our study
might need to be enhanced by further studies with large
real world cohorts of patients with NVAF. In the non-
anticoagulated cohort, the vast majority of patients were
taking antiplatelet therapy during follow up. However,
antiplatelet therapy alone is not a substitute for thrombo-
embolic prevention in AF and could not reduce sig-
nificantly the TE risk [21], so patients in the non-
anticoagulated cohorts continue to have high TE risk
during the follow up.
Really, most patients in the non-anticoagulated cohort
were at risk of TE event and despite this, the anticoagu-
lation was underused in these patients. This may be
mainly due to the effect of advance age, associated
comorbidities and/or patient preference on the medical
decisions taken by the emergency department doctors
and the reluctance to change the medication regime.
Conclusions
CHA2DS2-VASc has better association with TE events
than R2CHADS2 or ATRIA in non-anticoagulated pa-
tients with NVAF, and represents in this study the more
accurate clinical tool for TE risk stratification in these
patients. The CHA2DS2-VASc and the R2CHADS2scores may accurately identify patients at truly low risk
of developing future TE events regardless of the anticoa-
gulation status.
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